SABCS 2022: Trials Show Improved Outcomes in HR+, HER2- Breast Cancer
The CAPItello-291, monarchE, RIGHT Choice, and EMERALD trials have shown favorable outcomes for patients with HR+, HER2- breast cancer.
Please login or register first to view this content.
